Latest news with #S&PBiotech
Yahoo
25-04-2025
- Business
- Yahoo
Healthcare sector under pressure as market weighs Trump impact
The S&P Biotech sector (XBI) has outperformed the S&P 500 (^GSPC) since 2021. Yahoo Finance Senior Health Reporter Anjalee Khemlani sits down with Catalysts host Madison Mills to take a closer look at the healthcare sector (XLV), specifically Medpace Holdings (MEDP) and Intuitive Surgical (ISRG), as uncertainty grows on the impact of President Trump's policy changes. To watch more expert insights and analysis on the latest market action, check out more Catalysts here.
Reuters
31-03-2025
- Health
- Reuters
Analysts at Cantor, formerly headed by Lutnick, call for Kennedy's dismissal
March 31 (Reuters) - Analysts at Cantor Fitzgerald, formerly headed by the Trump administration's Secretary Of Commerce Howard Lutnick, called for the dismissal of Secretary of Health and Human Services Robert F. Kennedy Jr. Kennedy, a well-known vaccine skeptic, last week announced plans to reshape the federal public health agencies that could involve firing thousands of workers. here. Cantor analysts Josh Schimmer and Eric Schmidt said in a note on Monday that Kennedy was "undermining the trusted leadership of health care in this country. HHS cannot be led by an anti-vax, conspiracy theorist with inadequate training." The note came after reports that the Food and Drug Administration's top vaccine official, Peter Marks, was forced to resign, the most high-profile exit at the regulator as the Trump administration undertakes an overhaul of federal health agencies. Lutnick, the billionaire who was the CEO of Cantor for 40 years, stepped down last month to run Trump's commerce department, handing over the reins of the brokerage in part to his two sons. Brandon Lutnick was appointed as chairman and Kyle Lutnick was named as executive vice chairman of Cantor. Cantor Fitzgerald did not immediately respond to Reuters' request for a comment. The ouster of Marks led to a decline in biotech and vaccine stocks on Monday. The SPDR S&P Biotech ETF closed down 3.9%. The Cantor analysts noted the fall in the stocks, but said their note had nothing to do with politics, stocks and biopharmaceutical sales, but with keeping lives out of jeopardy. They said they had learned from sources that Marks, who was willing to stay at the FDA, took a scientifically driven review of vaccine safety and did not yield to an anti-science agenda that undermined public health. The same could not be said about Kennedy, they said. The analysts also said the "administration has shown an ability to correct course, to compromise and to make changes where needed," adding they are "hopeful that the leaders in Washington will recognize and appreciate the benefits that vaccines can and should play in protecting U.S. citizens."
